ArticleAnnals of medicine and surgery (2012)2026
Early rituximab and structured rehabilitation drive rapid functional restoration in steroid- and PLEX-refractory NMOSD: a case report.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Neuromyelitis optica spectrum disorder (NMOSD) is an antibody-mediated central nervous system disorder, typically presenting with optic neuritis (ON) and longitudinally extensive transverse myelitis (LETM). Detection of anti-aquaporin 4 (AQP4) antibodies establishes the diagnosis, even in patients without classic clinical features. Case presentation: A 32-year-old female presented with progressive ascending quadriparesis and sensory deficits. Neurological examination revealed significant hypotonia and weakness, more pronounced in the lower limbs. Spinal magnetic resonance imaging showed LETM involving cervical and thoracic segments, correlating with symptoms. AQP4-IgG positivity confirmed the diagnosis of NMOSD. The patient showed no improvement with intravenous methylprednisolone and plasmapheresis. Subsequent early initiation of Rituximab, combined with comprehensive physiotherapy, resulted in significant functional recovery within a follow-up period of 1 year. Clinical discussion: NMOSD variably presents with limited or atypical presentations. Early-stage disease may be easily overlooked, particularly in the absence of classical optical or spinal symptoms. Early recognition followed by timely initiation of pharmacotherapy and prompt escalation to targeted immunotherapy like Rituximab - which depletes peripheral B cells and reduces pathogenic AQP4-IgG antibody production targeting disease pathophysiology - can lead to significant neurological improvement. When combined with comprehensive physiotherapy, these interventions support motor recovery, enhance mobility, and improve overall quality of life. Conclusion: Early recognition of NMOSD and timely escalation to Rituximab, especially when first-line therapies fail, can drive meaningful neurological recovery. Coordinated physiotherapy further strengthens functional outcomes, highlighting the importance of an integrated therapeutic approach in severe or refractory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.